Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (121-130 of 209) with videos related to

Pageof 21
Sort By:
European Urology Oncology|March 14, 2020
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerBenjamin Miron, Jean H Hoffman-Censits, Fern Anari, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
Cancer|June 1, 2019
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancerAlberto Martini, Rachel Jia, Bart S Ferket, et al.
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
European Urology|July 6, 2019
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial CancerLi Wang, Yixuan Gong, Abdel Saci, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Cancer Research Communications|May 15, 2024
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort EvaluationLaura Bukavina, Rashida Ginwala, Mohamed Eltoukhi, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Pageof 21

Showing results (121-130 of 209) with videos related to

Sort By:
Pageof 21
European Urology Oncology|March 14, 2020
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerBenjamin Miron, Jean H Hoffman-Censits, Fern Anari, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
Cancer|June 1, 2019
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancerAlberto Martini, Rachel Jia, Bart S Ferket, et al.
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
European Urology|July 6, 2019
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial CancerLi Wang, Yixuan Gong, Abdel Saci, et al.
Cancer Cell|February 15, 2014
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapyWoonyoung Choi, Sima Porten, Seungchan Kim, et al.
Cancer Research Communications|May 15, 2024
Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-institutional Prospective Cohort EvaluationLaura Bukavina, Rashida Ginwala, Mohamed Eltoukhi, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2018
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, et al.
Pageof 21